Clarity’s PSMA Imaging Agent Shows Superior Performance in Key Prostate Cancer Study

Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) just unveiled an update.

Clarity Pharmaceuticals has reported that results from the investigator-initiated Co-PSMA phase II trial of its copper-64 based PSMA imaging agent, 64Cu-SAR-bisPSMA, have been published in the high-impact journal European Urology, reinforcing earlier data presented at the European Association of Urology Congress. The study in men with early biochemical recurrence of prostate cancer after radical prostatectomy showed that 24-hour 64Cu-SAR-bisPSMA PET/CT more than doubled lesion detection per patient versus 68Ga-PSMA-11, delivered markedly higher true positive rates, and drove management changes in 44% of patients, shifting many from observation to active therapy and enabling more precise radiotherapy planning.

The publication highlights improved tumour-to-background contrast, higher lesion uptake, and near-perfect inter-reader agreement for 64Cu-SAR-bisPSMA, leading experts to describe it as the first PSMA-targeted agent to demonstrate significantly superior imaging characteristics over current standards. Clarity’s management says the accumulating evidence from Co-PSMA, COBRA and PROPELLER underpins its bid to make SAR-bisPSMA a new gold standard in PSMA PET, as it advances the registrational phase III AMPLIFY trial and pivotal CLARIFY study and prepares for commercial launch with capacity to supply more than 2 million copper-64 doses annually, positioning the company to compete aggressively in the blockbuster PSMA imaging market.

The most recent analyst rating on (AU:CU6) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.

More about Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals is an ASX-listed, clinical-stage radiopharmaceutical company focused on developing next-generation copper-64 based PSMA-targeted imaging agents for cancer, particularly prostate cancer. The company aims to penetrate the large and growing PSMA PET imaging market with its SAR-bisPSMA platform, supported by an emerging global supply and manufacturing footprint for commercial-scale dose production.

Average Trading Volume: 2,106,606

Technical Sentiment Signal: Sell

Current Market Cap: A$1.22B

For an in-depth examination of CU6 stock, go to TipRanks’ Overview page.